FDA reviews Empagliflozin's potential for arresting progression of chronic kidney disease Dr. Kamal Kant Kohli25 Jan 2023 2:45 PM GMTUSA: Jardiance (empagliflozin) tablets have received the supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA)....
Extreme hot and cold temperatures linked to increased cardiovascular deaths Dr. Kamal Kant Kohli13 Dec 2022 10:15 PM GMTResearchers have found in a new study spanning five continents that extremely hot and cold temperatures were linked to excess cardiovascular deaths,...
AstraZeneca Gets CDSCO panel nod to Import, Market Anti-Diabetic Dapagliflozin for Additional Indication Dr. Divya Colin23 Oct 2022 6:00 AM GMTNew Delhi: Pharmaceutical major AstraZeneca has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard...
Allopurinol fails to improve CV outcomes in ischemic heart disease patients: ALL-HEART trial Dr.Niharika Harsha B12 Oct 2022 3:00 PM GMTA recent study found that allopurinol did not improve the primary outcomes in cardiovascular patients aged 60 years or older with ischemic heart...
Asundexian promising oral anticoagulant in post-myocardial infarction patients Dr. Kamal Kant Kohli15 Sep 2022 2:30 PM GMTResearchers have found in a new study that Asundexian was a promising oral anticoagulant in post-myocardial infarction patients.Asundexian 50 mg...
SGLT2 inhibitors useful for HF patients with mildly reduced and preserved ejection fraction: Deliver Trial Dr. Kamal Kant Kohli7 Sep 2022 5:30 AM GMTPrevious studies have shown that the SGLT2 inhibitor dapagliflozin reduces cardiovascular mortality and morbidity in patients with diabetes, chronic...
Long-term use of evolocumab tied to sustained reduction of LDL C and CV events: FOURIER-OLE trial Dr. Kamal Kant Kohli3 Sep 2022 5:30 AM GMTEvolocumab is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor used to lower CVD risk by controlling LDL cholesterol.According to...
Empagliflozin improves symptoms, reduces hospitalization in HF patients: EMPEROR-preserved Trial Dr.Niharika Harsha B30 Jun 2022 2:00 PM GMTResearchers have found in EMPEROR-preserved trial that in heart failure patients symptoms were improved, primary outcomes were reduced and...
Low vessel fractional flow reserve after percutaneous coronary intervention to fail Dr. Nandita Mohan1 Jun 2022 3:30 AM GMTBoth fractional flow reserve and non-hyperemic pressure ratios are widely used to assess the hemodynamic importance of intermediate coronary artery...
Early Initiation of SGLT2 inhibitors Benefits Heart Failure Patients MD Bureau13 April 2022 5:30 AM GMTHeart failure (HF) is a growing public health issue. The increasing burden of HF on health care is primarily due to an ageing population, as evidenced...
Warmer nights may lead to more cardiovascular deaths among men Dr. Kamal Kant Kohli4 April 2022 3:30 AM GMT Warmer than usual summer nights appear to lead to an increase in cardiovascular deaths in men aged in their early 60s but not women, suggests new...
Routine invasive therapy does not reduce major ischemic events: ISCHEMIA Trial MD Editorial Team16 Feb 2022 3:30 AM GMTIschemia is a serious concern as some part of the body, vital organs such as heart or brain, isn't getting enough blood. Approximately 1.5 million...
